AI Article Synopsis
- Pneumocystis carinii pneumonia (PCP) is often seen in patients with weakened immune systems, like those with AIDS or blood cancers, but is rarely reported in solid tumor patients.
- This report discusses three gastric cancer patients who developed PCP after receiving dexamethasone as an antiemetic during chemotherapy, with varying doses and durations of treatment.
- The study suggests that PCP can be effectively managed in gastric cancer patients if healthcare providers maintain a high level of clinical suspicion and initiate prompt treatment, and it provides foundational data on dexamethasone dosage related to PCP risk.
Article Abstract
Pneumocystis carinii pneumonia (PCP) has rarely been reported in solid tumor patients. It is a well-known complication in immunosuppressed states including acquired immune deficiency syndrome and hematologic malignancy. PCP has been reported in solid tumor patients who received long-term steroid treatment due to brain or spinal cord metastases. We found 3 gastric cancer patients with PCP, who received only dexamethasone as an antiemetic during chemotherapy. The duration and cumulative dose of dexamethasone used in each patient was 384 mg/48 days, 588 mg/69 days, and 360 mg/42 days, respectively. These cases highlight that the PCP in gastric cancer patients can successfully be managed through clinical suspicion and prompt treatment. The cumulative dose and duration of dexamethasone used in these cases can be basic data for risk of PCP development in gastric cancer patients during chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392316 | PMC |
| http://dx.doi.org/10.4174/jkss.2012.83.1.50 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!